Nantong Jinghua Pharmaceutical Co Ltd (002349) - Total Assets
Based on the latest financial reports, Nantong Jinghua Pharmaceutical Co Ltd (002349) holds total assets worth CN¥3.62 Billion CNY (≈ $529.26 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nantong Jinghua Pharmaceutical Co Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Nantong Jinghua Pharmaceutical Co Ltd for the company's overall valuation and market capitalisation.
Nantong Jinghua Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Nantong Jinghua Pharmaceutical Co Ltd's total assets of CN¥3.62 Billion consist of 56.8% current assets and 43.2% non-current assets. Review total liabilities of Nantong Jinghua Pharmaceutical Co Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.0% |
| Accounts Receivable | CN¥321.92 Million | 9.0% |
| Inventory | CN¥277.32 Million | 7.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥58.68 Million | 1.6% |
| Goodwill | CN¥167.94 Million | 4.7% |
Asset Composition Trend (2006–2025)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 002349 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nantong Jinghua Pharmaceutical Co Ltd's current assets represent 56.8% of total assets in 2025, an increase from 38.3% in 2006.
- Cash Position: Cash and equivalents constituted 24.0% of total assets in 2025, up from 5.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, unchanged from 5.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 9.0% of total assets.
Nantong Jinghua Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nantong Jinghua Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Nantong Jinghua Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.43 | 4.99 | 2.60 |
| Quick Ratio | 4.67 | 4.24 | 2.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.60 Billion | CN¥1.50 Billion | CN¥886.22 Million |
Nantong Jinghua Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nantong Jinghua Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | CN¥3.57 Billion |
| Market Capitalization | $963.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nantong Jinghua Pharmaceutical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nantong Jinghua Pharmaceutical Co Ltd's assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nantong Jinghua Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total assets of Nantong Jinghua Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.57 Billion ≈ $522.45 Million |
+8.13% |
| 2024-12-31 | CN¥3.30 Billion ≈ $483.15 Million |
+3.67% |
| 2023-12-31 | CN¥3.19 Billion ≈ $466.07 Million |
+4.71% |
| 2022-12-31 | CN¥3.04 Billion ≈ $445.09 Million |
-4.89% |
| 2021-12-31 | CN¥3.20 Billion ≈ $467.98 Million |
+1.33% |
| 2020-12-31 | CN¥3.16 Billion ≈ $461.83 Million |
+7.30% |
| 2019-12-31 | CN¥2.94 Billion ≈ $430.41 Million |
-13.48% |
| 2018-12-31 | CN¥3.40 Billion ≈ $497.48 Million |
+4.88% |
| 2017-12-31 | CN¥3.24 Billion ≈ $474.35 Million |
+28.10% |
| 2016-12-31 | CN¥2.53 Billion ≈ $370.29 Million |
+0.97% |
| 2015-12-31 | CN¥2.51 Billion ≈ $366.72 Million |
+32.84% |
| 2014-12-31 | CN¥1.89 Billion ≈ $276.06 Million |
+76.18% |
| 2013-12-31 | CN¥1.07 Billion ≈ $156.69 Million |
+11.81% |
| 2012-12-31 | CN¥957.71 Million ≈ $140.14 Million |
+22.70% |
| 2011-12-31 | CN¥780.53 Million ≈ $114.22 Million |
+27.66% |
| 2010-12-31 | CN¥611.41 Million ≈ $89.47 Million |
+177.45% |
| 2009-12-31 | CN¥220.37 Million ≈ $32.25 Million |
+12.46% |
| 2008-12-31 | CN¥195.95 Million ≈ $28.67 Million |
-2.08% |
| 2007-12-31 | CN¥200.11 Million ≈ $29.28 Million |
+0.97% |
| 2006-12-31 | CN¥198.19 Million ≈ $29.00 Million |
-- |
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also pr… Read more